New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma

被引:0
|
作者
Puzyrenko, Andrii [1 ]
Cortina, Chandler S. [1 ]
Jorns, Julie M. [1 ]
机构
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
关键词
PAX8; triple-negative breast cancer; metastasis; serous carcinoma; PAX8; EXPRESSION; NEUROENDOCRINE TUMORS; NEOPLASMS; UTILITY; SITE; CELL;
D O I
10.1177/10668969221084268
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
While screening has improved early detection of primary breast cancers, it may also identify metastasis to the breast in rare instances. High-grade carcinomas identified on breast screening may have non-specific morphology and immunoprofiles, making distinction from metastasis problematic. High-grade carcinomas frequently lose expression of specific tumor markers. New evidence specifically challenges GATA3/PAX8 exclusivity in the differential diagnosis of high-grade triple-negative breast cancer and high-grade serous carcinoma of mullerian origin. This case series provides a careful and detailed review of immunohistochemistry interpretation, with focus on PAX8, and the potential pitfalls in making a definitive pathological diagnosis, which is essential in determining oncological treatment options.
引用
收藏
页码:728 / 733
页数:6
相关论文
共 50 条
  • [1] Immunohistochemistry in the Differential Diagnosis of High-Grade Serous and Triple Negative Breast Carcinomas: Old and New Markers
    Jain, Pragya Virendrakumar
    Molina, Mariel
    Moh, Michelle
    Bishop, Erin
    Rader, Janet
    Jorns, Julie
    LABORATORY INVESTIGATION, 2023, 103 (03) : S665 - S666
  • [2] The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer
    Amr Ahmed El-Arabey
    Mohnad Abdalla
    Human Cell, 2022, 35 : 1298 - 1300
  • [3] The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer
    El-Arabey, Amr Ahmed
    Abdalla, Mohnad
    HUMAN CELL, 2022, 35 (04) : 1298 - 1300
  • [4] Somatic mutations in triple-negative breast carcinoma and high-grade serous ovarian carcinoma from young women.
    Serio, Pedro Adolpho M. P.
    Lima Pereira, Glaucia Fernanda
    Hirata Katayama, Maria Lucia
    Maistro, Simone
    Mendoza Lopez, Rossana Veronica
    Roela, Rosimeire Aparecida
    Rodrigues, Livia Munhoz
    Koike Folgueira, Maria A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer
    Fusco, Nicola
    Geyer, Felipe C.
    De Filippo, Maria R.
    Martelotto, Luciano G.
    Ng, Charlotte K. Y.
    Piscuoglio, Salvatore
    Guerini-Rocco, Elena
    Schultheis, Anne M.
    Fuhrmann, Laetitia
    Wang, Lu
    Jungbluth, Achim A.
    Burke, Kathleen A.
    Lim, Raymond S.
    Vincent-Salomon, Anne
    Bamba, Masamichi
    Moritani, Suzuko
    Badve, Sunil S.
    Ichihara, Shu
    Ellis, Ian O.
    Reis-Filho, Jorge S.
    Weigelt, Britta
    MODERN PATHOLOGY, 2016, 29 (11) : 1292 - 1305
  • [6] Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
    Lonning, Per E.
    Nikolaienko, Oleksii
    Pan, Kathy
    Kurian, Allison W.
    Eikesdal, Hans P.
    Pettinger, Mary
    Anderson, Garnet L.
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Knappskog, Stian
    JAMA ONCOLOGY, 2022, 8 (11) : 1579 - 1587
  • [7] Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences
    Serio, Pedro Adolpho de Menezes Pacheco
    de Lima Pereira, Glaucia Fernanda
    Katayama, Maria Lucia Hirata
    Roela, Rosimeire Aparecida
    Maistro, Simone
    Folgueira, Maria Aparecida Azevedo Koike
    CELLS, 2021, 10 (12)
  • [8] Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.
    Lonning, Per Eystein
    Nikolaienko, Oleksii
    Pan, Kathy
    Kurian, Allison W.
    Eikesdal, Hans Petter Petter
    Pettinger, Mary
    Anderson, Garnet L.
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Knappskog, Stian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer.
    Batalini, Felipe
    Gulhan, Doga
    Mao, Victor
    Polak, Madeline
    Winer, Eric P.
    Mayer, Erica L.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    Park, Peter
    Wulf, Gerburg M.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Serous-Like Breast Carcinoma: A Novel Subtype of Triple-Negative Breast Cancer
    Ghosh, Toshi
    Goetz, Matthew
    Visscher, Daniel
    MODERN PATHOLOGY, 2019, 32